Use of inmunoconjugado with anti-cd19 Antibody for the treatment of symptoms maitansinoide B cell tumors

摘要

Claim 1: a method to treat the symptom of CD19 + B cell tumors in a patient who requires, wherein Said method comprises administering to the patient a therapeutically effective amounts of the inmunoconjugado maitansinoide anti-cd19.Claim 2: a method according to claim 1, in which the inmunoconjugado administered with a dosing regimen that reduces the toxicity resulting from treatment. Claim 3: a method according to any one of claims 1 and 2, in which toxicity is ocular toxicity resulting in adverse events related to the eye.Claim 6: a method to treat the symptom of CD19 + B cell tumors in a patient in need,Where the said method comprises the steps of administering to the patient a dose of approximately 55 mg / m2 of inmunoconjugado of maitansinoide anti-cd19; and administering to the patient a Plurality of subsequent doses of approximately 55 mg / m2 of inmunoconjugado of maitansinoide anti CD19,Where subsequent doses are separated in time by intervals of approximately one week. A method according to claim 12: any one of claims 1 to 11, where this Symptom in CD19 + B cell tumors is a symptom or a symptom leukaemia Lymphoma.A method according to claim 20: claim 13, wherein Said Symptom non Hodgkin's Lymphoma is a disease resistant to rituximab. A method according to claim 30: any one of claims 1 to 29, in which the inmunoconjugado of maitansinoide anti-cd19 has the formula (1).Claim: inmunoconjugado 38 of maitansinoide anti-cd19 to treat a Human Patient diagnosed with symptomatic malignant tumor of CD19 + cells.Via A method which comprises the steps of administering to the patient a dose of approximately 55 mg / m2 of inmunoconjugado of maitansinoide anti-cd19; and administering to the patient a Plurality of subsequent doses of approximately 55 mg / m2 of inmunoconjugado of maitansinoide Anti-cd19,Where subsequent doses are separated in time by intervals of approximately one week.Claim 40: a manufactured Article comprising: a) a packaging material; (b) a inmunoconjugado of maitansinoide anti-cd19; and (c) a Label or package leaflet contained within the packaging material, which indicates that the inmunoconjugado of maitansinoide anti-cd19 are The patient was administered at an initial dose of approximately 55 mg / m2And a Plurality of subsequent doses, separated in time by approximately one week intervals, in a quantity that is approximately 55 mg / m2.